Pfizer Triumphs in the Billion-Dollar Poker! Victory over Metsera Strengthens Attack in the GLP-1 Market!
Reading Time: 4 minutes
Pfizer (PFE) has won the months-long bidding war against Novo Nordisk with the acquisition of the US biotech company Metsera, securing a crucial position in the booming market for obesity and metabolic medications. The approximately $10 billion deal not only marks Pfizer's comeback in the GLP-1 segment but also represents a strategic turning point in the global competition for the next generation of weight loss drugs. Metsera - The Newcomer Power in the Obesity Market Metsera is a New York-based clinical biotech company focused on novel therapies...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
